{"id":"NCT01274637","sponsor":"Ottawa Hospital Research Institute","briefTitle":"PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot","officialTitle":"Postpartum Prophylaxis for PE Randomized Control Trial Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2011-01-11","resultsPosted":"2017-08-01","lastUpdate":"2017-08-01"},"enrollment":62,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thromboembolism","Postpartum"],"interventions":[{"type":"DRUG","name":"Dalteparin Sodium","otherNames":["Fragmin","Dalteparin Sodium(DIN 02132648/NDC# 62856-500)"]}],"arms":[{"label":"low molecular weight heparin","type":"EXPERIMENTAL"},{"label":"Control Group","type":"NO_INTERVENTION"}],"summary":"The purpose of this study is to determine if it is feasible to conduct a multi-center randomized trial to determine whether a blood thinner, low-molecular-weight-heparin (LMWH), is effective at preventing blood clots, thromboembolism (VTE), in postpartum women at risk.","primaryOutcome":{"measure":"Feasibility of Recruitment and Trial Operations.","timeFrame":"4 months","effectByArm":[{"arm":"Low Molecular Weight Heparin","deltaMin":0.9,"sd":null},{"arm":"Control Group","deltaMin":0.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["United States","Canada"]},"refs":{"pmids":["27096813","25373438","33779986"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":30},"commonTop":["Cellulitis","Cellulitis","Abnormal Lab result"]}}